A Case of Severe Asthma with Eosinophilic Otitis Media Successfully Treated with Anti-IgE Monoclonal Antibody Omalizumab

Table 2

The clinical course before and after omalizumab treatment.

Omalizumab; dose pack (months)	Before; treatment	Post 2 months; (5~8 W)	Post 4 months; (13~16 W)	Post 6 months; (21~24 W)	After; 1 year
IgE (IU/mL)	97.4	181	159	144	102
PEF (L/sec): morning/evening	210/290	280/330	280/310	220/280	230/320
PSL dose (mg/day)	15	10	10	10/5	15
Rescue frequency; (times/28 day)	12	0	0	7	10
Daily life (days/28 days)
No difficulty	0	5	28	16	4
Slight difficulty	19	23		7	24
Extreme difficulty	9			5
Deep sleep (days/28 days)	20	28	28	24	28
Cough    Mild	15	14	8	7	9
(days/28 days)   strong	3	0	1	5	0
none	9	14	19	16	16
No symptom days; (days/28 days)	20	28	27	21	25
Lung function: FEV1 (L)	1.93		2.34
% FEV1 (% )	63.9		76.4
PEF (L/sec)	4.89		5.84